...
首页> 外文期刊>Journal of Surgical Oncology >Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases.
【24h】

Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases.

机译:肝切除术加上术中射频消融和化学疗法可治疗难以切除的多发性大肠肝转移。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Results and indications of intra-operative radiofrequency (RF) ablation of liver metastases (LM) are not well defined in the literature. AIM: To appreciate the survival rate of patients with strictly unresectable LM (defined on technical but not oncological criteria) when undergoing liver resection plus RF, along with optimal systemic chemotherapy. PATIENTS AND METHODS: Sixty three patients with technically unresectable LM (either >5, or bilateral with no sparing of at least one sector of the liver, or with tumor proximity to central major vascular structures) were treated. Extrahepatic metastases were also resected in 27% of patients. All patients received perioperative chemotherapy. The median follow-up was 27.6 months (range: 15-74). RESULTS: There was no postoperative mortality and the morbidity rate was 27%. The 2-year overall survival rate of the 63 patients was 67% with a median survival of 36 months. The local recurrence rates were similar for the three types of local treatments: 7.1% for the 154 RF ablations, 7.2% for the 55 wedge resections, and 9% for the 44 segmental anatomic resections (P = 0.216). Hepatic recurrences occurred in 71% of patients. CONCLUSION: The combination of anatomic segmental and wedge resections, RF ablation, and optimal chemotherapy in patients with technically unresectable LM results in a median survival of 36 months.
机译:背景:文献中对肝转移灶(LM)术中射频消融的结果和指征尚无明确定义。目的:了解接受严格的不可切除的LM(根据技术标准而非肿瘤学标准定义)进行肝切除+ RF以及最佳全身化疗的患者的生存率。患者和方法:治疗了63例技术上不可切除的LM患者(> 5,或双侧,没有保留至少一个肝脏区域,或肿瘤靠近中央主要血管结构)。肝外转移也被切除了27%的患者。所有患者均接受围手术期化疗。中位随访时间为27.6个月(范围:15-74)。结果:无术后死亡,发病率为27%。 63名患者的2年总生存率为67%,中位生存期为36个月。三种局部治疗的局部复发率相似:154例RF消融的7.1%,55例楔形切除的7.2%和44例节段性解剖的9%(P = 0.216)。肝复发发生在71%的患者中。结论:对于无法手术切除的LM患者,结合解剖学段和楔形切除术,RF消融术和最佳化学疗法,可以使中位生存期为36个月。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号